Osmotica Pharmaceuticals plc to Host UPNEEQ® Overview and Business Update Call on January 19, 2022
Osmotica Pharmaceuticals (Nasdaq: OSMT) announced a conference call on January 19, 2022, at 8:30 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Osmotica Pharmaceuticals (Nasdaq: OSMT) announced a conference call on January 19, 2022, at 8:30 a.m. ET. Key executives, including CEO Brian Markison and COO JD Schaub, will discuss UPNEEQ® trends, plans for entering the medical aesthetics market, and other business updates. Shareholders can access the live webcast here. The event will also be available for replay on the company’s website under the “Investor & News” section.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRIDGEWATER, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and other key speakers, will host a call to discuss recent UPNEEQ® trends, pending expansion into the medical Aesthetics market and other general business updates as follows:
| Date: | Wednesday, January 19, 2022 |
| Time: | 8:30 a.m. ET |
| Webcast: | https://experience.v-unite.com/#/aestheticrecorddemo/rvlinvestorday/room/welcome |
The webcast will be available thereafter via the Company’s website at www.rvlpharma.com under the “Investor & News” section.
About Osmotica Pharmaceuticals plc
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) is a specialty pharmaceutical company focused on the development and commercialization of products that target markets with underserved patient populations. RVL Pharmaceuticals, Inc., is the Company’s ophthalmic and medical aesthetics subsidiary supporting UPNEEQ®.
Investor and Media Relations for Osmotica Pharmaceuticals plc
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.